Tereza Planck1,2, Bushra Shahida1, Johan Malm3, Jonas Manjer1,4. 1. Department of Clinical Sciences Malmö, Lund University, Malmö, Sweden. 2. Department of Endocrinology, Skåne University Hospital, Malmö, Sweden. 3. Department of Translational Medicine, Section for Clinical Chemistry, Lund University, Malmö, Sweden. 4. Department of Surgery, Skåne University Hospital, Malmö, Sweden.
Abstract
OBJECTIVE: The aim was to compare the vitamin D levels in patients with Graves disease (GD) with the general population and to correlate the vitamin D levels with laboratory and clinical parameters in GD. Moreover, we examined the genetic variation in genes involved in the vitamin D metabolism and their association with GD. METHODS: The levels of vitamin D were compared in 292 patients with newly diagnosed GD and 2,305 controls. Single nucleotide polymorphisms (SNPs) in the vitamin D receptor (VDR), vitamin D binding protein (DBP), and 1-α-hydroxylase (CYP27B1) were examined for association with GD and/or Graves ophthalmopathy (GO) in 708 patients and 1,178 controls. RESULTS: Patients with GD had significantly lower vitamin D levels compared to controls (55.0 ± 23.2 vs. 87.2 ± 27.6 nmol/L, p < 0.001). In patients with GD (n = 219), there was no association between the levels of vitamin D at diagnosis and free thyroxine (fT4), free triiodothyronine (fT3), thyrotropin receptor antibodies (TRAb), GO at diagnosis, or relapse after terminating treatment with antithyroid drugs. Two SNPs in VDR were associated with GD: rs10735810 (OR = 1.36, 95% CI: 1.02-1.36, p = 0.02) and rs1544410 (OR = 1.47, 95% CI: 1.03-1.47, p = 0.02). There was no difference in the mean vitamin D level between genotypes in either rs10735810 or rs154410. CONCLUSIONS: Patients with GD had lower vitamin D levels compared to the general population; however, the vitamin D levels did not affect the laboratory or clinical parameters of GD. SNPs in the VDR influenced the risk of GD through mechanisms other than reducing the vitamin D levels.
OBJECTIVE: The aim was to compare the vitamin D levels in patients with Graves disease (GD) with the general population and to correlate the vitamin D levels with laboratory and clinical parameters in GD. Moreover, we examined the genetic variation in genes involved in the vitamin D metabolism and their association with GD. METHODS: The levels of vitamin D were compared in 292 patients with newly diagnosed GD and 2,305 controls. Single nucleotide polymorphisms (SNPs) in the vitamin D receptor (VDR), vitamin D binding protein (DBP), and 1-α-hydroxylase (CYP27B1) were examined for association with GD and/or Graves ophthalmopathy (GO) in 708 patients and 1,178 controls. RESULTS: Patients with GD had significantly lower vitamin D levels compared to controls (55.0 ± 23.2 vs. 87.2 ± 27.6 nmol/L, p < 0.001). In patients with GD (n = 219), there was no association between the levels of vitamin D at diagnosis and free thyroxine (fT4), free triiodothyronine (fT3), thyrotropin receptor antibodies (TRAb), GO at diagnosis, or relapse after terminating treatment with antithyroid drugs. Two SNPs in VDR were associated with GD: rs10735810 (OR = 1.36, 95% CI: 1.02-1.36, p = 0.02) and rs1544410 (OR = 1.47, 95% CI: 1.03-1.47, p = 0.02). There was no difference in the mean vitamin D level between genotypes in either rs10735810 or rs154410. CONCLUSIONS: Patients with GD had lower vitamin D levels compared to the general population; however, the vitamin D levels did not affect the laboratory or clinical parameters of GD. SNPs in the VDR influenced the risk of GD through mechanisms other than reducing the vitamin D levels.
Entities:
Keywords:
Graves disease; Graves ophthalmopathy; Vitamin D; Vitamin D receptor
Authors: A L Lauridsen; P Vestergaard; A P Hermann; C Brot; L Heickendorff; L Mosekilde; E Nexo Journal: Calcif Tissue Int Date: 2005-05-05 Impact factor: 4.333
Authors: S Khamisi; M Lundqvist; A J Rasmusson; B E Engström; F A Karlsson; Ö Ljunggren Journal: J Endocrinol Invest Date: 2022-09-27 Impact factor: 5.467
Authors: Swayamsidha Mangaraj; Arun K Choudhury; Basanta M Swain; Pradosh K Sarangi; Binoy K Mohanty; Anoj K Baliarsinha Journal: Indian J Endocrinol Metab Date: 2019 Jan-Feb
Authors: D Gallo; L Mortara; M B Gariboldi; S A M Cattaneo; S Rosetti; L Gentile; D M Noonan; P Premoli; C Cusini; M L Tanda; L Bartalena; E Piantanida Journal: J Endocrinol Invest Date: 2019-10-04 Impact factor: 5.467